Lazzeri Elena, Romagnani Paola, Lasagni Laura
a University of Florence; Excellence Centre for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE) , Florence, Italy +390552758342 ;
Expert Opin Biol Ther. 2015;15(10):1455-68. doi: 10.1517/14712598.2015.1067300. Epub 2015 Jul 10.
Kidney diseases are a global public health problem whose incidence is rapidly growing due to a global rise in the aged population and the increasing prevalence of cardiovascular disease, hypertension and diabetes. With the emergence of stem cells as potential therapeutic agents, attempts in using them to significantly reduce the burden of these diseases have increased.
Several types of stem cells have been proven to be likely candidates for treating kidney diseases. We discuss in detail the potential use of mesenchymal stem cells in preclinical and clinical works, with additional populations that have been studied briefly described. Moreover, we discuss current knowledge on endogenous kidney regeneration ability and on the possibility to modulate it using chemical and biological agents.
Stem cell therapy is a promising new treatment for kidney disease documented in many animal studies. Mesenchymal stem cells have emerged as a promising cell type, but their efficacy in clinical trials is still controversial. Identification of progenitor cells in the adult kidney is another step forward in regenerative medicine, suggesting the repair potential of the adult kidney and the possible modulation of renal progenitors in situ using pharmacological approaches.
肾脏疾病是一个全球性的公共卫生问题,由于全球老年人口的增加以及心血管疾病、高血压和糖尿病患病率的上升,其发病率正在迅速增长。随着干细胞作为潜在治疗剂的出现,利用它们显著减轻这些疾病负担的尝试也在增加。
几种类型的干细胞已被证明可能是治疗肾脏疾病的候选者。我们详细讨论了间充质干细胞在临床前和临床工作中的潜在用途,并简要描述了其他已研究的细胞群体。此外,我们还讨论了目前关于内源性肾脏再生能力以及使用化学和生物制剂调节这种能力的可能性的知识。
干细胞疗法是一种有前景的肾脏疾病新疗法,许多动物研究都有记载。间充质干细胞已成为一种有前景的细胞类型,但其在临床试验中的疗效仍存在争议。在成体肾脏中鉴定祖细胞是再生医学的又一进展,这表明成体肾脏具有修复潜力,并且可能利用药理学方法原位调节肾祖细胞。